GGrantIndex
Sort

48,018 grants matching immunotherapy

Drug Development for Prostate Cancer

$782,938
William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

PROJECT 1: TIME-Based Spatiotemporal Cancer Immunograms Predictive for Immunotherapy-Targeted Therapy Sequential Combinations

$782,862
James R. Heath · Institute For Systems Biology · U54 · FY2025 · CA

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy

$782,809
Matthew Joel Feinstein · Northwestern University At Chicago · R01 · FY2023 · HL

Myocardial Vulnerability to Ischemia-Induced Dysfunction and Heart Failure: The Impact of HIV/SIV, ART, and Targeted Immunotherapy

$782,809
Matthew Joel Feinstein · Northwestern University At Chicago · R01 · FY2022 · HL

TOLERANCE TO ISLET ALLOGRAFTS IN TYPE I DIABETES

$782,709
University Of Minnesota Twin Cities · R01 · FY2001 · DK

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$782,691
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2023 · CA

Role of gamma/delta T cells in Vaccine Induced Immunity

$782,578
Daniel F. Hoft · Saint Louis University · R01 · FY2017 · AI

Immunophysiological Mechanisms in the Biological Therapy of Cancer

$782,272
Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Mechanisms of myocarditis and progressive cardiac fibrosis in chronic Trypanosoma cruzi infection.

$781,984
Kathryn Marie Jones · Baylor College Of Medicine · R01 · FY2024 · AI

Mechanistic Core

$781,625
Lloyd F Mayer · Icahn School Of Medicine At Mount Sinai · U19 · FY2015 · AI

B cell-dependent anti-tumor immunity in ovarian cancer

$781,585
Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2021 · CA

B cell-dependent anti-tumor immunity in ovarian cancer

$781,585
Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2019 · CA

B cell-dependent anti-tumor immunity in ovarian cancer

$781,585
Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2018 · CA

Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

$781,552
Madhav V Dhodapkar · Emory University · U54 · FY2020 · CA

ACTIVE IMMUNOTHERAPY FOR COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME

$781,497
Howard Feldman · University Of California, San Diego · R01 · FY2015 · AG

Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques

$781,408
Leslie S Kean · Seattle Children'S Hospital · R01 · FY2014 · HL

Basis for Success of Multidrug-Resistant Enterobacteriaceae

$781,350
Frank Deleo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Role of Th17 in Severe and Recurrent C. difficile Infection

$781,166
William A Petri · University Of Virginia · R01 · FY2021 · AI

Quantitative Endogenous MRI Imaging of Neuroinflammation in AD

$781,126
Qing Wang · Washington University · R01 · FY2022 · AG

Reprogramming the Tumor-Immune Interface in Oral Cancer

$780,996
John B Sunwoo · Stanford University · R35 · FY2020 · DE

Effects of genetic polymorphism in MHC, KIR, and related loci on human disease

$780,882
Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

How Does blockade of CD40/CD40L Prevent Autoimmunity?

$780,672
La Jolla Inst For Allergy &Immunolgy · U19 · FY2002 · AI

Shared Resource: Comparative Medicine

$780,585
Gordon Roble · Fred Hutchinson Cancer Research Center · P30 · FY2021 · CA

Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients

$780,553
Zhongxing Liao · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · HL

Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia

$780,389
Pietro Genovese · Boston Children'S Hospital · R01 · FY2024 · CA